Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients

ClinicalTrials.gov ID: NCT00643227

Public ClinicalTrials.gov record NCT00643227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Clarithromycin Extended Release for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults

Study identification

NCT ID
NCT00643227
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
504 participants

Conditions and interventions

Conditions

Interventions

  • azithromycin SR Drug
  • clarithromycin extended release (ER) Drug

Drug

Eligibility (public fields only)

Age range
16 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2002
Primary completion
Not listed
Completion
Feb 29, 2004
Last update posted
Mar 25, 2008

2003 – 2004

United States locations

U.S. sites
36
U.S. states
13
U.S. cities
27
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35215
Pfizer Investigational Site Birmingham Alabama 35242
Pfizer Investigational Site Haleyville Alabama 35565
Pfizer Investigational Site Montgomery Alabama 36106
Pfizer Investigational Site Montgomery Alabama 36109
Pfizer Investigational Site Tallassee Alabama 36078
Pfizer Investigational Site Mesa Arizona 85201
Pfizer Investigational Site Phoenix Arizona 85014
Pfizer Investigational Site Tempe Arizona 85282
Pfizer Investigational Site La Jolla California 92037
Pfizer Investigational Site San Diego California 92128
Pfizer Investigational Site Orlando Florida 32806
Pfizer Investigational Site Boise Idaho 83703
Pfizer Investigational Site Boise Idaho 83704
Pfizer Investigational Site Boise Idaho 83706
Pfizer Investigational Site Boise Idaho 83709
Pfizer Investigational Site Boise Idaho 83713
Pfizer Investigational Site Meridian Idaho 83642
Pfizer Investigational Site Nampa Idaho 83651
Pfizer Investigational Site Chalmette Louisiana 70043
Pfizer Investigational Site New Orleans Louisiana 70112
Pfizer Investigational Site New Orleans Louisiana 70128
Pfizer Investigational Site Butte Montana 59701
Pfizer Investigational Site Holmdel New Jersey 07733
Pfizer Investigational Site Clemmons North Carolina 27012
Pfizer Investigational Site Salisbury North Carolina 28144
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Charleston South Carolina 29406
Pfizer Investigational Site Summerville South Carolina 29485
Pfizer Investigational Site Milan Tennessee 38358
Pfizer Investigational Site Salt Lake City Utah 84102
Pfizer Investigational Site Salt Lake City Utah 84109
Pfizer Investigational Site Salt Lake City Utah 84121
Pfizer Investigational Site Taylorsville Utah 84118
Pfizer Investigational Site West Jordan Utah 84088
Pfizer Investigational Site Casper Wyoming 82601

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00643227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 25, 2008 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00643227 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →